Agios Pharmaceuticals (AGIO) Total Non-Current Liabilities (2021 - 2026)
Agios Pharmaceuticals (AGIO) has disclosed Total Non-Current Liabilities for 9 consecutive years, with $75.8 million as the latest value for Q1 2026.
- For Q1 2026, Total Non-Current Liabilities fell 13.99% year-over-year to $75.8 million; the TTM value through Mar 2026 reached $75.8 million, down 13.99%, while the annual FY2025 figure was $104.0 million, 14.29% down from the prior year.
- Total Non-Current Liabilities hit $75.8 million in Q1 2026 for Agios Pharmaceuticals, down from $104.0 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $164.0 million in Q3 2024 and bottomed at $75.8 million in Q1 2026.
- Average Total Non-Current Liabilities over 5 years is $115.0 million, with a median of $116.4 million recorded in 2023.
- Year-over-year, Total Non-Current Liabilities skyrocketed 37.49% in 2024 and then plummeted 38.23% in 2025.
- Agios Pharmaceuticals' Total Non-Current Liabilities stood at $134.6 million in 2022, then fell by 7.19% to $124.9 million in 2023, then dropped by 2.87% to $121.4 million in 2024, then dropped by 14.29% to $104.0 million in 2025, then dropped by 27.14% to $75.8 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $75.8 million, $104.0 million, and $101.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.